Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gossamer Bio, Inc.NASDAQ: GOSS
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 98.6%
Gross margin was 98.6% in Q1 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 99.6%, down 0.4 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 97.9%
- Year-over-year change
- -2.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.9% | -2.1pp |
| FY2024 | 2024-12-31 | 100.0% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 gross margin of 99.6% is the highest of the 7 companies compared; the peer median is 69.4%.
- Its year-over-year change of -0.4 pp is the 4th highest of 6, against a peer median of +3.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 99.6% | -0.4 pp | — | |
| LTM Mar 2026 | 99.1% | +83.0 pp | +37780.7 pp | |
| LTM Mar 2026 | 93.4% | +3.7 pp | -5.2 pp | |
| LTM Dec 2025 | 92.0% | — | — | |
| LTM Mar 2026 | 46.8% | -53.2 pp | -38.2 pp | |
| LTM Mar 2026 | -0.1% | -76.7 pp | +36.5 pp | |
| LTM Mar 2026 | -12.4% | +490439.7 pp | +2555.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding GOSS) | 69.4% | +3.7 pp | +36.5 pp | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| Weighted Avg Shares | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
| Weighted Avg Shares (Diluted) | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.